MRC2 and mesothelioma: In this study, we use a modified anti-uPARAP ADC, based on a clinically validated payload, to study the utility of an ADC-based treatment in vivo, using both patient-derived and cell line–based mesothelioma xenograft mouse models with varying uPARAP expression profiles.